Karolinska University Hospital
- Address
- lock Available on a paid plan
Oncology (Neoplasms)
The Department of Pelvic Cancer at Karolinska University Hospital conducts extensive research on solid tumours and haematologic malignancies, aiming to evaluate new therapeutic combinations and improve survival outcomes.
- Advanced epithelial ovarian cancer
- Advanced or recurrent endometrial cancer
- Renal cell carcinoma
- Breast cancer
- Prostate cancer
- Melanoma
- Gastrointestinal stromal tumour
- Neuroblastoma
- Liposarcoma
- Non‑small cell lung cancer
- Pancreatic ductal adenocarcinoma
- Testicular germ‑cell tumours
Across more than 70 trials, investigators explore targeted agents, immunotherapies and precision‑medicine approaches to enhance treatment effectiveness.
Female Urogenital Diseases & Pregnancy
Research focuses on ovarian, endometrial and cervical malignancies as well as conditions such as preeclampsia, seeking to refine surgical timing and adjuvant strategies.
- Advanced epithelial ovarian cancer
- Endometrial cancer
- Cervical cancer
- Preeclampsia
- Endometriosis‑related pelvic pain
Trials evaluate peri‑operative interventions and novel hormonal regimens to improve reproductive health and cancer outcomes.
Immune System Disorders
The site investigates autoimmune skin conditions and inflammatory myopathies, testing biologics and small molecules to reduce disease activity.
- Cutaneous lupus erythematosus
- Dermatomyositis
- Polymyositis
- Alopecia areata
- Atopic dermatitis
- Idiopathic inflammatory myopathies
Efforts aim to modulate immune pathways and achieve durable remission with fewer side effects.
Cardiovascular & Metabolic
Clinical studies address heart failure, atherosclerotic disease and stroke prevention, evaluating novel oral agents and device‑based diagnostics.
- Chronic heart failure with reduced ejection fraction
- Atherosclerotic cardiovascular disease
- Ischemic stroke
- Atrial fibrillation
- Type 2 diabetes
The goal is to lower mortality and hospitalisation by integrating cardioprotective therapies.
Digestive System Research
Investigations target gastrointestinal cancers and inflammatory bowel disease, seeking better chemotherapeutic schedules and biomarker‑guided treatment.
- Gastric cancer
- Gastroesophageal junction carcinoma
- Crohn’s disease
- Pancreatic ductal adenocarcinoma
- Colorectal cancer
Precision diagnostics such as genetic phenotyping guide therapeutic choices.
Neurology & Neurodegeneration
Trials explore Parkinson’s disease, stroke recovery and brain tumour imaging, aiming to preserve cognition and motor function.
- Parkinson’s disease
- Acute ischemic stroke
- Brain tumour
- Neuroblastoma (pediatric CNS involvement)
- Cognitive decline after radiotherapy
Advanced imaging with PET/CT and neuroprotective agents are central to these studies.
Hematologic & Lymphoid Cancers
The department conducts studies on B‑cell lymphomas, acute leukaemias and chronic lymphocytic leukaemia, focusing on antibody‑drug conjugates and emerging cellular therapies.
- Diffuse large B‑cell lymphoma
- Follicular lymphoma
- Acute lymphoblastic leukaemia (pediatric)
- Chronic lymphocytic leukaemia
- Mature aggressive B‑cell lymphoma
Therapies aim to increase overall response rates while minimizing toxicity.
Rare & Pediatric Oncology
Special attention is given to rare sarcomas, germ‑cell tumours and paediatric solid tumours, testing radioligand therapy and targeted inhibitors.
- Dedifferentiated liposarcoma
- Malignant extragonadal germ‑cell tumour
- High‑risk neuroblastoma
- Gastrointestinal stromal tumour
- Pediatric B‑cell lymphoma
Safety and long‑term outcomes are evaluated through longitudinal follow‑up.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 34 therapeutic areas and 15 of 664 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 621 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 143 by active trials.
- 1Karolinska University Hospital41active
lock +142 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Karolinska University Hospital54trials
lock +84 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Karolinska University Hospital
lock Showing 1 of 590 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | Bayer AG, Bayer Consumer Care AG | Phase II | Not Recruiting | Jun 2016 | Sep 2025 |
IMP list
lock Showing 1 of 664 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 40 | Unknown | 2016-11-17 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.